search
Back to results

Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus

Primary Purpose

Diabetes Mellitus, Non-Insulin-Dependent

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
stem cells
Sponsored by
Postgraduate Institute of Medical Education and Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Non-Insulin-Dependent

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • • Patients with type 2 diabetes mellitus between 30 and 65 years of age.

    • Duration of diabetes ≥ 5 years.
    • Failure to triple OHA in optimal doses {glimepiride (4 gm), metformin(2-2.5 gm) and pioglitazone(15mg)}.
    • Requiring insulin therapy for last six month
    • On stable doses of insulin (≥0.4 IU/kg/day, Vildagliptin, metformin (2 gm), pioglitazone (15mg) for last three months.
    • GAD antibody negative status.

Exclusion Criteria:

  • Patients with type 1 diabetes mellitus or secondary diabetes
  • Patients with serum creatinine > 1.5 mg/dL
  • Abnormal liver function tests (defined as value of transaminases > 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory).
  • History of cholecystitis/ cholelithiasis/ cholecystectomy.
  • Seropositivity for HIV, HBsAg and HCV.
  • History of myocardial infarction or unstable angina or any cardiovascular events in the previous 3 months.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Active Comparator

    Arm Label

    Intravenous

    superior pancreaticoduodenal

    splenic artery

    Arm Description

    stem cells will be injected through intravenously in the subjects

    stem cells

    stem cells will be injected through splenic in the subjects

    Outcomes

    Primary Outcome Measures

    Increase in glucagon stimulated C peptide level

    Secondary Outcome Measures

    Full Information

    First Posted
    October 19, 2015
    Last Updated
    October 22, 2015
    Sponsor
    Postgraduate Institute of Medical Education and Research
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02585505
    Brief Title
    Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus
    Official Title
    Tissue Distribution of F18-FDG Labeled Autologous Bone Marrow Derived Stem Cells in Patients With Type2 Diabetes Mellitus
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    December 2010 (undefined)
    Primary Completion Date
    June 2012 (Actual)
    Study Completion Date
    December 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Postgraduate Institute of Medical Education and Research

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Stem cells have promising potential in treating diabetes. However the therapeutic outcome in diabetic patients will profoundly depend on their delivery to pancreas. Our objective is to label stem cells with PET tracer F18-FDG to carry out in vivo cell tracking. The labeled stem cells will be given through different routes (intravenous and intraarterial)and tissue distribution studied. Patients will be followed up for the next 6 months. Glucagon stimulated C peptide will be measured at baseline and at 6 months and HOMA IR and HOMA beta will be calculated.
    Detailed Description
    Our objective is to label stem cells with PET tracer F18-FDG to carry out in vivo cell tracking. The labeled stem cells will be given through different routes (intravenous and intraarterial)and tissue distribution studied. Patients will be followed up for the next 6 months. Glucagon stimulated C peptide will be measured at baseline and at 6 months and HOMA IR and HOMA beta will be calculated.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus, Non-Insulin-Dependent

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    21 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Intravenous
    Arm Type
    Active Comparator
    Arm Description
    stem cells will be injected through intravenously in the subjects
    Arm Title
    superior pancreaticoduodenal
    Arm Type
    Active Comparator
    Arm Description
    stem cells
    Arm Title
    splenic artery
    Arm Type
    Active Comparator
    Arm Description
    stem cells will be injected through splenic in the subjects
    Intervention Type
    Procedure
    Intervention Name(s)
    stem cells
    Intervention Description
    stem cell will be injected
    Primary Outcome Measure Information:
    Title
    Increase in glucagon stimulated C peptide level
    Time Frame
    6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: • Patients with type 2 diabetes mellitus between 30 and 65 years of age. Duration of diabetes ≥ 5 years. Failure to triple OHA in optimal doses {glimepiride (4 gm), metformin(2-2.5 gm) and pioglitazone(15mg)}. Requiring insulin therapy for last six month On stable doses of insulin (≥0.4 IU/kg/day, Vildagliptin, metformin (2 gm), pioglitazone (15mg) for last three months. GAD antibody negative status. Exclusion Criteria: Patients with type 1 diabetes mellitus or secondary diabetes Patients with serum creatinine > 1.5 mg/dL Abnormal liver function tests (defined as value of transaminases > 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory). History of cholecystitis/ cholelithiasis/ cholecystectomy. Seropositivity for HIV, HBsAg and HCV. History of myocardial infarction or unstable angina or any cardiovascular events in the previous 3 months.

    12. IPD Sharing Statement

    Learn more about this trial

    Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus

    We'll reach out to this number within 24 hrs